Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation

• Published in: Acta pharmacologica Sinica Vol. 38; no. 1; pp. 69 - 79
• Main Authors: Meng, Qiang, Duan, Xing-ping, Wang, Chang-yuan, Liu, Zhi-hao, Sun, Peng-yuan, Huo, Xiao-kui, Sun, Hui-jun, Peng, Jin-yong, Liu, Ke-xin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.01.2017; Nature Publishing Group
• Subjects: Animals; Biomedical and Life Sciences; Biomedicine; Chenodeoxycholic Acid - pharmacology; Cholestenones - antagonists & inhibitors; Cholestenones - pharmacology; Choline Deficiency; Dose-Response Relationship, Drug; Fibrosis - pathology; Gene Expression - drug effects; Hepatocytes - metabolism; Immunology; Internal Medicine; Lipid Metabolism - drug effects; Lipogenesis - drug effects; Liver - enzymology; Liver - metabolism; Liver - pathology; Male; Medical Microbiology; Methionine - deficiency; Mice; Non-alcoholic Fatty Liver Disease - prevention & control; Original; original-article; Pharmacology/Toxicology; Pregnenediones - pharmacology; Primary Cell Culture; Protective Agents - pharmacology; Receptors, Cytoplasmic and Nuclear - agonists; Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors; Vaccine; 受体拮抗剂; 法尼醇; 激活作用; 肝炎病毒; 脂肪合成; 荧光定量PCR; 酒精性; 醋酸; CDCA; hepatic inflammation; guggulsterone; alisol B 23-acetate; farnesoid X receptor; hepatic fibrosis; non-alcoholic steatohepatitis
• ISSN: 1671-4083; 1745-7254; 1745-7254
• DOI: 10.1038/aps.2016.119

Alisol B 23-acetate （AB23A） is a natural triterpenoid isolated from the traditional Chinese medicine rhizoma alismatis, which exhibits a number of pharmacological activities, including anti-hepatitis virus, anti-cancer and antibacterial effects. In this study we examined whether AB23A protected against non-alcoholic steatohepatitis （NASH） in mice, and the mechanisms underlying the protective effects. NASH was induced in mice fed a methionine and choline-deficient （MCD） diet for 4 weeks. The mice were simultaneously treated with AB23A （15, 30, and 60 mg.kg^-1.d^-1, ig） for 4 weeks. On the last day, blood samples and livers were collected. Serum liver functional enzymes, inflammatoru markers were assessed. The livers were histologically examined using H＆E, Oil Red O, Masson＇s trichrome and Sirius Red staining. Mouse primary hepatocytes were used for in vitro experiments. The mechanisms underlying AB23A protection were analyzed using siRNA, qRT-PCR, and Western blot assays. AB23A treatment significantly and dose-dependently decreased the elevated levels of serum ALT and AST in MCD diet-fed mice. Furthermore, AB23A treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration and hepatic fibrosis in the mice. AB23A-induced decreases in serum and hepatic jipids were related to decreased hepatic lipogenesis through decreasing hepatic levels of SREBP-1c, FAS, ACC1 and SCD1 and increased lipid metabolism via inducing PPARa, CPTlc（, ACADS and LPL. The reduction in inflammatory cell infiltration corresponded to deceased serum levels of mKC and MCP-1 and decreased hepatic gene expression of MCP-1 and VCAM-I. The reduction in hepatic fibrosis was correlated with decreased hepatic gene expression of fibrosis markers. The protective effects of AB23A were FXR-dependent, because treatment with the FXR agonist CDCA mimicked AB23A-induced hepato-protection in the mice, whereas co-administration of FXR antagonist guggulsterone abrogated AB23A-induced hepato-protection. In mouse primary hepatocytes, FXR gene silencing abrogated AB23A-induced changes in gene expression of Apo C-II, CPT1α, ACADS and LPL. AB23A produces protective effects against NASH in mice via FXR activation.